At-Home Molecular Testing Market Revenue is Expected to Reach US$16.3 Billion by the end of 2030, By Persistence Market Research
January 17, 2024 00:58 ET
|
Persistence Market Research
New York, Jan. 17, 2024 (GLOBE NEWSWIRE) -- At-Home Molecular Testing Market: A Booming Frontier in Healthcare At-Home Molecular Testing refers to the use of molecular diagnostic tests conducted in...
P23 Health E-Commerce Well-Being Company Just Launched in Partnership With P23 Labs, a Renowned Molecular Laboratory
November 03, 2022 09:15 ET
|
P23 Health
SAVANNAH, Ga., Nov. 03, 2022 (GLOBE NEWSWIRE) -- P23 Health is a newly formed digital healthcare and wellness company under the P23 umbrella. P23 Health's strategic partner is acknowledged molecular...
MAKO Medical Invests in New Laboratory Automation
July 18, 2022 07:10 ET
|
MAKO Medical
RALEIGH, N.C., July 18, 2022 (GLOBE NEWSWIRE) -- MAKO Medical Laboratories, a national reference laboratory and national leader in COVID-19 testing, is purchasing four additional high-tech liquid...
Genetic Testing Market is projected to reach USD 36.11 Billion by 2030, growing at a CAGR of 10%: Straits Research
June 16, 2022 15:40 ET
|
Straits Research
New York, United States, June 16, 2022 (GLOBE NEWSWIRE) -- Genetic testing examines DNA to find gene mutations linked to a wide range of hereditary illnesses. There are multiple forms of genetic...
Current Signed Customers Expected to Generate $1M Annualized Reported Revenues from Precipio’s HemeScreen POL Offering by Q4-2021
April 26, 2021 11:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., April 26, 2021 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that currently, the contracted annualized revenues from signed customers...
Precipio Signs Sales & Marketing Agreement for HemeScreen™ with Major Oncology Distributor
December 10, 2020 10:15 ET
|
Precipio, Inc.
NEW HAVEN, Conn., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) has entered into an agreement with a major US-based oncology distributor to...
Interpace Diagnostics Labs Receive College of American Pathology (CAP) Accreditation
April 25, 2019 06:55 ET
|
Interpace Diagnostics Group, Inc.
Pennsylvania and Connecticut Labs Both Receive Accreditation PARSIPPANY, NJ, April 25, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it has...
Interpace Diagnostics Announces New York State Approval
April 23, 2019 06:55 ET
|
Interpace Diagnostics Group, Inc.
State of New York Approves Commercialization of ThyraMIR® Now in Three Specimens PARSIPPANY, NJ, April 23, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today...
In-vitro Diagnostic Services Market worth over $63 billion by 2024: Global Market Insights, Inc.
September 13, 2018 06:00 ET
|
Global Market Insights, Inc
Sellbyville, Delaware, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Global In-vitro Diagnostic Services Market is poised to cross USD 63 billion by 2024; according to a new research report by Global Market...
IASLC邀请肺癌专业人士参与全球分子诊断调查
July 12, 2018 16:11 ET
|
IASLC
丹佛, July 13, 2018 (GLOBE NEWSWIRE) -- 国际肺癌研究协会（IASLC）鼓励所有参与肺癌患者分子诊断的人员参加一项全球调查，本调查旨在评估最佳实务的实施情况及最终制定分子诊断的全球指南。欲参加IASLC肺癌分子诊断全球调查，请访问www.iaslc.org/survey。 IASLC的医学博士、哲学博士和首席执行官Fred R....